Clinical Kidney Journal最新文献

Background: Magnesium (Mg) deficiency seems to be associated with altered bone metabolism and vascular calcifications (VC). This study aimed to evaluate the association between serum Mg levels and incident bone fragility fractures and VC in a cohort of prevalent hemodialysis (HD) patients.

Methods: We performed a retrospective study of 206 patients, with a mean age of 68.3 ± 13.1 years; 121 (59%) were male, and the median follow-up time was 58 months.

Results: Thirty-seven episodes of fragility fractures were identified with a median HD vintage of 42 months-an incidence rate of 29 per 1000 person-years. Patients with fractures showed lower Mg levels compared with those without fractures (P < .001) and more VC (P = .01). In a Cox regression analysis, time to fragility fracture was independently associated with serum Mg <2.2 mg/dL (P < .001), in a model adjusted to age, female gender, HD vintage, diabetes mellitus, body mass index, albumin, parathyroid hormone, active vitamin D therapy and the presence of VC. Patients with Mg serum levels <2.2 mg/dL had a 1.32-fold higher risk of fragility fractures (P < .001).

Conclusions: This study showed that the incidence of bone fragility fractures in HD patients is high and is significantly associated with lower Mg levels and with the presence of more VC.

The progressive loss of kidney function in diabetes mellitus is partly attributable to the occurrence of glomerular hyperfiltration. Consequently, therapeutic interventions that lower intra-glomerular pressure are a cornerstone of treatment in diabetic kidney disease. Sodium-glucose cotransporter 2 (SGLT2) inhibitors consistently reduce glomerular filtration rate (GFR) and calculated intraglomerular pressures across studies. However, the net effect on arteriolar tone that leads to acute GFR declines may differ between cohorts. While pre-glomerular vasoconstriction appears to be the dominant mechanism responsible for GFR dipping in patients with type 1 diabetes (T1D) and glomerular hyperfiltration, other factors, including post-glomerular vasodilation, may contribute to the acute GFR decline in normofilterering individuals with T1D and type 2 diabetes. Regardless of the responsible mechanisms, acute changes in GFR are associated with long-term kidney function preservation-a relationship that may reflect an underlying protective decline in glomerular hypertension.

Background: Neurovascular coupling (NVC), as indicated by a comprehensive analysis of the amplitude of low-frequency fluctuation (ALFF) and cerebral blood flow (CBF), provides mechanistic insights into neurological disorders. Patients undergoing peritoneal dialysis (PD) and hemodialysis (HD) often face cognitive impairment, the causes of which are not fully understood.

Methods: ALFF was derived from functional magnetic resonance imaging, and CBF was quantified using arterial spin labeling in a cohort comprising 58 patients with PD, 60 patients with HD and 62 healthy controls. Voxel-based global analysis for both ALFF and CBF, alongside region-based analyses of ALFF-CBF coupling coefficients, were conducted. Additionally, the study explored the correlation between clinical laboratory indices and imaging metrics.

Results: Compared with HC, NVC was reduced in the bilateral medial superior frontal gyrus (SFGmed), insula, posterior cingulate cortex (PCC) and caudate (CAU) among dialysis patients. Furthermore, the PD group exhibited lower NVC in the bilateral SFGmed, bilateral PCC and left CAU compared with the HD group. Within the PD group, sodium level was negatively correlated with the ALFF-CBF coupling coefficient in the right insula. Additionally, a positive correlation emerged between the ALFF-CBF coupling coefficient in bilateral SFGmed and the dialysis adequacy.

Conclusion: While Montreal Cognitive Assessment scores did not significantly differ between patients with PD and HD, PD group demonstrated poorer NVC in the bilateral SFGmed, bilateral PCC and left CAU. Sodium level and dialysis adequacy may affect NVC in patients with PD.

Background: Sarcopenia and frailty are often overlooked in assessing kidney transplant (KT) candidates with chronic kidney disease (CKD), potentially leading to poor post-transplant outcomes. This study aimed to identify metabolites associated with frailty and sarcopenia in KT candidates from the FRAILMar study.

Methods: Between June 2016 and June 2020, we evaluated frailty and sarcopenia in 173 KT candidates using the Physical Frailty Phenotype and EGWSOP-2 criteria, respectively. Seventy-five metabolic markers from targeted pathways, previously linked to CKD, sarcopenia or frailty, were measured in serum samples. These markers were analyzed using adjusted and weighted generalized linear models. Metabolomic data were integrated with multi-modal data, such as comorbidities, using a factor-based integration algorithm to identify metabolic phenotypes.

Results: Increased metabolites related to energy metabolism and essential amino acids were associated with frailty, mainly Krebs cycle intermediates. Sarcopenic KT candidates showed lower levels of aromatic amino acids, and lower protein/muscle metabolism, energy metabolism and neurotransmission compared with non-sarcopenic patients. Unsupervised multi-modal integration revealed a high-risk metabolic phenotype characterized by the presence of sarcopenia, diabetes mellitus and low body mass index, with alterations in branched-chain amino acids and high activity of lactate dehydrogenase enzyme.

Conclusions: Frailty and sarcopenia are common among KT candidates, and their metabolic status reveals notable disruptions in energy and amino acid metabolism. These findings highlight the value of a detailed metabolic assessment to more accurately evaluate patient health status prior to transplantation.

Introduction: It remains unclear whether persisting proteinuria in ANCA-associated glomerulonephritis (AAGN) reflects damage from the initial injury or ongoing inflammation.

Methods: A retrospective, single-centre study of biopsy-proven AAGN was performed. The study defined the 'albuminuria' group as urine albumin-to-creatinine ratio (ACR) >300 mg/g and the 'no albuminuria' group as ACR ≤300 mg/g at 6 months. We sought the clinical and histopathological characteristics of both the initial and subsequent biopsies and long-term kidney outcomes stratified by albuminuria levels.

Results: Two hundred and eighteen patients were included. Within the first 6 months, 28 (13%) died or progressed to end-stage kidney disease (ESKD). Among the remaining 190 patients, 37% had an ACR >300 mg/g at 6 months. The albuminuria group more frequently presented with a Berden mixed or crescentic class and had higher glomerular activity on the initial biopsy. They were more often male (OR 2.75; 95% CI 1.15-6.54), younger age (OR 0.96; 95% CI 0.93-0.99), and had fewer normal glomeruli in the biopsy (OR 0.96; 95% CI 0.93-0.99) compared with the group without albuminuria. Over the initial 5-year period, the recovery in eGFR was lower in the albuminuria group (adjusted mean difference in ΔeGFR -12.5 mL/min per 1.73 m²; 95% CI -15.8 to -9.1). In multivariable analysis, ACR >300 mg/g was associated with a higher risk of ESKD, even after adjusting for Berden classification and eGFR at diagnosis (hazard ratio 6.53; 95% CI 1.49-28.50).

Conclusions: In a well-defined cohort of AAGN, one-third of the patients, primarily younger males with a lower percentage of normal glomeruli, had persisting albuminuria after induction treatment which was associated with worse kidney outcomes independent of Berden class and eGFR at diagnosis.

Background: Chronic kidney disease (CKD) is an important public health problem. Although cross-sectional studies have identified many heavy metals/trace elements associated with reduced kidney function, prospective studies are needed to determine the pathogenic role of these elements in the development and progression of CKD.

Methods: To explore the association between baseline urinary heavy metal/trace element concentrations and long-term impaired kidney function (IKF)/CKD, as well as the incidence of rapid decline in kidney function in a population-based exploratory prospective study, with mean age 51.9 years at baseline whose urinary trace elements concentrations have been determined by inductively coupled plasma mass spectrometry. IKF was defined by a reduced estimated glomerular filtration rate (eGFR) between 60 and 90 mL/min/1.73 m², and CKD was defined as an eGFR <60 mL/min/1.73 m². Rapid eGFR decline was defined as a decrease ≥3 mL/min/1.73 m²/year.

Results: Over a mean follow-up of 12.5 years, 123 participants (2.6%) experienced rapid decline in kidney function, and 1455 (31.7%) developed IKF or CKD. After adjusting for covariates including baseline eGFR, we found that urinary vanadium [hazard ratio (HR) = 1.07, 1.03-1.12], cobalt (HR = 1.69, 1.21-2.37), nickel (HR = 1.19, 1.08-1.3), copper (HR = 1.03, 1.01-1.06), selenium (HR = 1.33, 1.02-1.73), molybdenum (HR = 1.48, 1.2-1.82) and iodine (HR = 1.1, 1.02-1.2) were associated with an increased risk of new incident IKF or CKD cases during the follow-up. Also, urinary copper [odds ratio (OR) = 1.12, 1.04-1.21], silver (OR = 1.83, 1-3.35), molybdenum (OR = 1.02, 1.01-1.04) and cadmium (OR = 1.05, 1.01-1.09) were associated with an increased risk of rapid eGFR decline.

Conclusion: In the general population, several urinary heavy metals/trace elements are associated with a rapid decline in kidney function or new cases of IKF/CKD.

Background: Kidney exchange programmes (KEPs) have revolutionized living donor kidney transplantation (LDKT) by enabling transplants for patients with HLA- or ABO-incompatible donors. However, the implications for donors participating in KEPs, particularly regarding postoperative health-related quality of life (HRQoL), are not well elucidated. This study compares the HRQoL of donors participating in KEPs with donors donating directly (non-KEPs).

Methods: The study included 724 donors, with 121 in the KEP group and 603 in the non-KEP group. Outcomes were assessed using the mental component summary (MCS), physical component summary (PCS), EQ-5D-3L, MVI-20 score, and self-rated pain level. We used a mixed-effects regression model to assess differences between KEP and non-KEP over time, accounting for repeated measures within subjects.

Results: There was a significant temporary decline in both the MCS and PCS post-donation; however, these outcomes returned to pre-donation levels after an interval of 2 months. Donors participating in the KEP had higher PCS and MCS 1-year post-donation. Comparable results were observed in the self-assessed HRQoL using the EQ-5D-3L instrument, as well as in the fatigue scores measured by the MVI-20.

Conclusions: We found that participation in KEPs does not adversely affect donors' short- or long-term mental and physical HRQoL outcomes and that LDKT donors have HRQoL of pre-donation levels soon after donation. These insights are reassuring, indicating that donors participating in KEPs can expect HRQoL comparable to those who do not. This reinforces the viability of KEPs as a safe option for expanding LDKT and findings can inform patient and donor education.

Background: Lysinuric protein intolerance (LPI) is a metabolic disorder that leads to dysfunctional intestinal absorption and kidney clearance of cationic amino acids. Chronic kidney disease develops in many LPI patients and leads to end-stage kidney disease in at least 10% of patients. Since data on kidney transplants in LPI patients are limited, we analysed the outcomes of LPI patients after transplantation in Finland.

Methods: This retrospective cohort study includes all Finnish LPI patients who have received a kidney transplant. The data were collected from the Finnish Transplant Registry and electronic medical records from 2005 through May 2023 or patient death. The plasma amino acid profile was analysed before and after transplantation.

Results: Eight LPI patients (75% female, mean age at transplant 41.9 years) received a kidney allograft and two of the patients received a second transplant. Nine transplants were from deceased donors and one was from a living donor. Acute rejection occurred after four transplantations (two T-cell mediated and two antibody mediated). One patient died 6 months after transplantation due to alveolar proteinosis. Apart from lower citrulline and higher lysine concentrations, plasma amino acid levels showed no changes after transplantation. The 1-, 5- and 10-year graft survivals were 80%, 68.6% and 51.4%, and patient survivals were 88%, 86% and 50%, respectively.

Conclusions: Kidney transplantation is feasible in patients with LPI, although the acute rejection rate seems high and severe complications such as pulmonary alveolar proteinosis may occur. Transplantation led to changes in plasma citrulline and lysine concentrations.